Aphria now able to export approved cannabis
products to international markets
LEAMINGTON, ON, Nov. 23, 2017 /CNW/ - Aphria Inc. ("Aphria" or
the "Company") (TSX: APH and US OTC: APHQF) achieved another
milestone as part of its expansion strategy, obtaining its Dealer's
License pursuant to the Controlled Drugs and Substances Act under
Health Canada. This permits the Company to possess, sell and
transport medical cannabis oil and resin to international
markets.
"There is an incredible appetite for high-quality medical
cannabis in legal markets around the world. Obtaining our Dealer's
License is a significant milestone in our international expansion
strategy as it enables Aphria to have greater control over
importing and exporting medical cannabis oil globally," said
Vic Neufeld, CEO of Aphria. "This
license will accelerate our speed to international markets and
broaden our patient base internationaly, resulting in greater
revenue for Aphria."
As mandated by Health Canada, import and export permits from the
relevant international and Canadian regulatory authorities, will be
required for all transactions to international markets.
Aphria is well positioned to meet the increasing international
demand for medical cannabis in legal markets like Australia, Italy, Germany and Argentina. Aphria is rapidly completing
its four-part expansion of its fully-funded facility in
Leamington, Ontario, which will
increase the greenhouse growing footprint to one million square
feet and increase our capacity to supply more than 100,000 kgs of
high-quality cannabis at one of the lowest costs in the
industry.
We Have a Good Thing Growing.
About Aphria
Aphria Inc., one of Canada's
lowest cost producers, produces, supplies and sells medical
cannabis. Located in Leamington,
Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight,
allowing for the most natural growing conditions available. Aphria
is committed to providing pharma-grade medical cannabis, superior
patient care while balancing patient economics and returns to
shareholders.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to internal expectations,
estimated international revenues, estimated margins, expectations
with respect to actual international shipments, expectations for
future growing capacity and costs, the completion of any capital
project or expansions, and expectations with respect to future
production costs. Forward-looking statements necessarily involve
known and unknown risks, including, without limitation, risks
associated with general economic conditions; adverse industry
events; marketing costs; loss of markets; future legislative and
regulatory developments involving medical marijuana; inability to
access sufficient capital from internal and external sources,
and/or inability to access sufficient capital on favourable terms;
the medical marijuana industry in Canada generally, future international
opportunities in the medical marijuana industry, income tax and
regulatory matters; the ability of Aphria to implement its business
strategies; competition; crop failure; currency and interest rate
fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
SOURCE Aphria Inc.